Australian Clinical Labs Ltd
ASX:ACL
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.41
3.78
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
ACL
stock under the Base Case scenario is
5.52
AUD.
Compared to the current market price of 2.79 AUD,
Australian Clinical Labs Ltd
is
Undervalued by 49%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Australian Clinical Labs Ltd.
| US |
|
CVS Health Corp
NYSE:CVS
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
|
| US |
|
Cigna Corp
NYSE:CI
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
|
| US |
|
Hims & Hers Health Inc
NYSE:HIMS
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
A sharp drop in pandemic-related testing volumes threatens to crimp ACL’s revenue and margin growth, as the company’s COVID-19 tailwind fades faster than anticipated.
Stronger competition from large, established rivals such as Sonic Healthcare and Healius puts pressure on ACL’s pricing power, potentially undermining its market-share expansion strategy in certain regions.
Rising labor costs and ongoing staff shortages in the pathology sector could squeeze ACL’s bottom line, particularly if wage inflation outpaces the company’s ability to implement productivity improvements.
ACL’s ability to deepen its footprint through strategic acquisitions, such as buying out smaller pathology firms, fosters economies of scale and enhances its bargaining power with suppliers.
Its focus on specialized testing services, including genomic and molecular diagnostics, positions ACL to capture higher-margin growth opportunities as healthcare providers increasingly pivot to advanced tests for personalized medicine.
Demographic tailwinds, notably Australia’s aging population and greater need for chronic disease monitoring, support ongoing demand for ACL’s pathology offerings and provide a resilient foundation for revenue growth.
Revenue & Expenses Breakdown
Australian Clinical Labs Ltd
Balance Sheet Decomposition
Australian Clinical Labs Ltd
| Current Assets | 120.1m |
| Cash & Short-Term Investments | 22.1m |
| Receivables | 72.8m |
| Other Current Assets | 25.1m |
| Non-Current Assets | 454.8m |
| Long-Term Investments | 2.5m |
| PP&E | 270.1m |
| Intangibles | 165.2m |
| Other Non-Current Assets | 17m |
| Current Liabilities | 216.4m |
| Accounts Payable | 51.6m |
| Other Current Liabilities | 164.8m |
| Non-Current Liabilities | 187.1m |
| Long-Term Debt | 181.8m |
| Other Non-Current Liabilities | 5.3m |
Free Cash Flow Analysis
Australian Clinical Labs Ltd
| AUD | |
| Free Cash Flow | AUD |
Earnings Waterfall
Australian Clinical Labs Ltd
|
Revenue
|
741.3m
AUD
|
|
Cost of Revenue
|
-128.2m
AUD
|
|
Gross Profit
|
613m
AUD
|
|
Operating Expenses
|
-545m
AUD
|
|
Operating Income
|
68m
AUD
|
|
Other Expenses
|
-35.6m
AUD
|
|
Net Income
|
32.4m
AUD
|
ACL Profitability Score
Profitability Due Diligence
Australian Clinical Labs Ltd's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
Australian Clinical Labs Ltd's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
ACL Solvency Score
Solvency Due Diligence
Australian Clinical Labs Ltd's solvency score is 24/100. The higher the solvency score, the more solvent the company is.
Score
Australian Clinical Labs Ltd's solvency score is 24/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ACL Price Targets Summary
Australian Clinical Labs Ltd
According to Wall Street analysts, the average 1-year price target for
ACL
is 3.42 AUD
with a low forecast of 2.93 AUD and a high forecast of 4.04 AUD.
Dividends
Current shareholder yield for
ACL is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
ACL
stock under the Base Case scenario is
5.52
AUD.
Compared to the current market price of 2.79 AUD,
Australian Clinical Labs Ltd
is
Undervalued by 49%.